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Background: Recombinant human interleukin 12 (rHuIL-12) regulates hematopoiesis and cell-mediated immunity.
Based on these hematopoietic and immunomodulatory activities, a recombinant human IL-12 (rHuIL-12) is now
under development to address the unmet need for a medical countermeasure against the hematopoietic syndrome
of the acute radiation syndrome (HSARS) that occurs in individuals exposed to lethal radiation, and also to serve as
adjuvant therapy that could provide dual hematopoietic and immunotherapeutic benefits in patients with cancer
receiving chemotherapy. We sought to demonstrate in healthy subjects the safety of rHuIL-12 at single, low doses
that are appropriate for use as a medical countermeasure for humans exposed to lethal radiation and as an
immunomodulatory anti-cancer agent.
Methods: Two placebo-controlled, double-blinded studies assessed the safety, tolerability, pharmacokinetics and
pharmacodynamics of rHuIL-12. The first-in-human (FIH) dose-escalation study randomized subjects to single
subcutaneous injections of placebo or rHuIL-12 at 2, 5, 10, and 20 μg doses. Due to toxicity, dose was reduced to
15 μg and then to 12 μg. The phase 1b expansion study randomized subjects to the highest safe and well tolerated
dose of 12 μg.
Results: Thirty-two subjects were enrolled in the FIH study: 4 active and 2 placebo at rHuIL-12 doses of 2, 5, 10, 12,
and 15 μg; 1 active and 1 placebo at 20 μg. Sixty subjects were enrolled in the expansion study: 48 active and 12
placebo at 12 μg dose of rHuIL-12. In both studies, the most common adverse events (AEs) related to rHuIL-12 were
headache, dizziness, and chills. No immunogenicity was observed. Elimination of rHuIL-12 was biphasic, suggesting
significant distribution into extravascular spaces. rHuIL-12 triggered transient changes in neutrophils, platelets,
reticulocytes, lymphocytes, natural killer cells, and CD34+ hematopoietic progenitor cells, and induced increases in
interferon-γ and C-X-C motif chemokine 10.
Conclusion: A single low dose of rHuIl-12 administered subcutaneously can elicit hematological and immune-mediated
effects without undue toxicity. The safety and the potent multilineage hematopoietic/immunologic effects triggered by
low-dose rHuIL-12 support the development of rHuIL-12 both as a radiation medical countermeasure and as adjuvant
immunotherapy for cancer.
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Interleukin-12 (IL-12), a heterodimeric cytokine with p40
and p35 subunits, is well-known for its pleiotropic effects.
Several in vitro studies in the early-mid nineties reported
that IL-12 is capable of stimulating hematopoiesis syner-
gistically with other cytokines [1-5]. The hematopoiesis-
promoting activity of IL-12 was suggested to be due to
a direct action on bone marrow stem cells, thereby
promoting the proliferation and/or differentiation of
hematopoietic progenitor cells [3,6,7]. In addition to
these hematopoietic effects of IL-12, the cytokine has
demonstrated potent immunomodulatory effects. For
example, IL-12 has been shown to play an essential
role in the interaction between the innate and adaptive
arms of immunity [6]. IL-12 has also been shown to
enhance cytolytic activity of macrophages, T cells, and
natural killer (NK) cells, and to stimulate the differen-
tiation of naïve T helper (TH) cells into TH1 cells
[8-12]. These immunomodulatory effects of IL-12 have
been widely studied in pre-clinical models of diseases
such as cancer [13,14], viral and parasitic infections
[15,16], and allergy [17]. The importance of immune-
mediated effects of IL-12 has been documented clinically
by the discovery that immunodeficient patients experien-
cing recurrent infections harbor mutations in IL-12 or
IL-12 receptor components [18,19]. IL-12 therapy also
has been shown to restore resistance to infection after
injury [20].
The effector mechanisms of IL-12 in innate resistance
and adaptive immunity have been explored in various
experimental tumor models, as reviewed by Colombo
and Trinchieri [21]. Promising data obtained in preclin-
ical models led to clinical trials in oncology patients with
the hope that IL-12 could be a powerful anticancer
therapeutic agent [21]. Indeed, immunomodulatory ef-
fects of IL-12 have been demonstrated in several human
cancers [22-24]. However, the high doses and repeat-
dosing regimens used in oncology trials generally re-
sulted in excessive clinical toxicity that was accompanied
by only a modest clinical response [21]. Various studies
have implicated interferon gamma (IFN-γ), the hallmark
of immune activation by IL-12, as an important medi-
ator of antitumor activity [13,14,25,26]. However Gollob
and colleagues found that induction of IFN-γ was mark-
edly attenuated after repeat dosing of rHuIL-12 [25], in-
dicating a tachyphylactic response. This inability to
maintain IFN-γ release may have contributed to reduced
tumor response rates in previous clinical trials of IL-12,
where high doses and frequent administration regimens
were used [21,26]. As these early phase trials did not
meet expectations, further clinical development of IL-12
was not pursued. These historical data underscore the
fact that anti-tumor potential of IL-12 has not been fully
realized.Based on its hematopoietic and immunomodulatory ac-
tivities, a recombinant human IL-12 (rHuIL-12) is now
under development to address the unmet need for a med-
ical countermeasure (MCM) against the hematopoietic
syndrome of the acute radiation syndrome (HSARS) that
occurs in individuals exposed to lethal radiation, and also
to serve as adjuvant therapy that could provide dual
hematopoietic and immunotherapeutic benefits in pa-
tients with cancer receiving chemotherapy. These devel-
opment paths are predicated on the use of single, low
doses of IL-12, which had been shown to facilitate en-
dogenous hematopoiesis in mice exposed to ionizing radi-
ation [27]. The development program for rHuIL-12 as a
medical countermeasure to lethal radiation exposure fol-
lows the FDA’s Animal Rule, where efficacy is determined
in appropriate animal models and safety is demonstrated
in humans [28]. To date, studies in irradiated non-human
primates (NHP) and mice have demonstrated the ability
of single, low doses of rHuIL-12 to induce recovery of
hematopoietic tissue following radiation-induced bone
marrow ablation and to decrease the incidence of
hemorrhage and infections, all of which lead to a substan-
tial increase in survival after exposure to lethal radiation
[6]. These studies underscore the potential of a single, low
dose of IL-12 to provide dual hematopoietic and immuno-
logic benefits. Herein, we report the results of two clinical
studies conducted in parallel to these animal efficacy stud-
ies to evaluate the safety and tolerability of single, low
doses of rHuIL-12 in normal healthy subjects. The first-
in-human (FIH) phase 1, dose-escalation study identified
the maximum tolerated dose (MTD) of rHuIL-12 based
on stringent toxicity criteria and the subsequent phase 1b
expansion study demonstrated the safety of the rHuIL-12
at the MTD in a larger sample of healthy adults. These
clinical safety studies support the development of rHuIL-
12 as a stand-alone frontline radiation MCM. An add-
itional important objective of these safety studies was to
assess the safety of initiating development of rHuIL-12 as
a multilineage hematopoietic and immunotherapeutic
agent in patients with cancer who are receiving aggressive
chemotherapy, where single doses of IL-12 are planned to
be used once per chemotherapy cycle.
Results
Subject disposition
In the FIH dose-escalation study, 32 subjects were
randomized: 21 subjects were randomized to rHuIL-
12 (4 each at doses of 2, 5, 10, 12, and 15 μg and 1 the
20 μg dose) and 11 were randomized to placebo (2 each
for doses of 2, 5, 10, 12, and 15 μg and 1 the 20 μg
dose). All 32 subjects completed the study. Nineteen
subjects (59%) were males and 13 (41%) were females;
mean age was 28 years (range: 18 to 44 years). Twenty-
six subjects (81%) were white, 2 (6%) were African
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races.
In the subsequent Phase 1b expansion study, 60 sub-
jects were randomized 4:1 to rHuIL-12 at the MTD
identified in the FIH study (12 μg) or placebo; thus 48
subjects were treated with rHuIL-12 and 12 subjects
were treated with placebo. Forty-nine subjects (82%)
were males and eleven (18%) were females; mean age
was 28 years (range: 18 to 45 years). Forty subjects
(67%) were white, 13 (22%) were African American and
7 (11%) were of other races. Fifty-eight subjects com-
pleted the study. Two subjects withdrew (one on Day 16
and other on Day 22) for personal reasons unrelated to
the study.
Safety and tolerability
All 32 subjects in the FIH study and all 60 subjects in
the phase 1b expansion study were analyzed for the pri-
mary endpoint.
FIH study
No serious AEs or AEs leading to discontinuation and
no clinically significant changes in clinical chemistry la-
boratory evaluations, vital sign measurements, physical
examinations, or 12-lead ECGs were observed in either
study. All AEs were resolved or recovered by the end of
the study. A summary of drug-related AEs in the FIH
study is presented in Table 1. The most frequent AEs re-
lated to rHuIL-12 treatment were headache, dizziness,
chills and injection site pain. All the AEs related to rHuIL-
12, were mild (grade 1) to moderate (grade 2), except for
three severe (grade 3) hematological AEs reported at the
two highest doses. These included lymphopenia (absolute
count of 400 lymphocytes/mm3) and thrombocytopenia
(absolute counts of 109,000 to 118,000 platelets/mm3 over
4 days) in the single subject treated at the 20 μg dose level,
and neutropenia (absolute counts of 700 to 1000 neutro-
phils/mm3 over 4 days) in 1 subject treated at the 15 μg
dose level. The severe AEs started 3 or 4 days after dosing
and continued for 3 to 4 days. The 2 events (grade 3 lym-
phopenia and grade 3 thrombocytopenia) occurring at the
20 μg dose level constituted dose-limiting toxicities
(DLTs), and led to dose reduction of rHuIL-12 to 15 μg.
Another DLT (grade 3 neutropenia) at 15 μg resulted in
dose reduction of rHuIL-12 to 12 μg. None of the severe
drug-related AEs required concomitant medication or
other action. The maximum tolerated dose of 12 μg was
further examined in the subsequent phase 1b expansion
study.
Phase 1b expansion study
A summary of drug-related AEs that occurred in ≥ 5%
subjects in the expansion study is presented in Table 2.
No subject treated with the single, 12 μg dose of rHuIL-12 used in this study experienced drug-related severe cy-
topenias, confirming the safety and tolerability observed
in the FIH study. The most frequently reported rHuIL-
12-related AEs were headache, dizziness, chills, fatigue,
myalgia and back pain. All the AEs related to rHuIL-12
were mild or moderate except for episodes of severe
chills and dizziness that occurred in the same subject be-
ginning 11 hours after dosing; both events resolved over
the next 5 hours, and neither required treatment or
other action. Thus, data from the expansion study con-
firmed the overall safety and tolerability of rHuIL-12 ob-
served in the FIH study, and expanded the size of the
population treated safely at the 12 μg dose level.
Pharmacokinetics
All subjects who received rHuIL-12 and had evaluable
data were included in the pharmacokinetic (PK) analysis.
Due to insufficient data in the terminal phase, exposure
parameters requiring extrapolation, such as AUC0-∞,
elimination half life, volume of distribution and clear-
ance, could not be reliably estimated in either study. The
initial half life was calculated within the time frame of 8
to 24 hours after dosing while the terminal half-life was
evaluated at later time points; the calculation for each
subject required at least 3 descending data points be-
yond 24 hours after dosing. Plasma concentration vs.
time profiles for rHuIL-12 are presented in Figure 1A
(FIH study) and 1B (expansion study). Figure 1B also
shows plasma concentration vs. time profiles for IFN-γ
and C-X-C motif chemokine 10 (CXCL10; also known as
IFN-γ-induced protein 10) in relation to rHuIL-12. These
pharmacodynamic (PD) results are discussed with other
PD results below.
FIH study
Mean PK parameters for rHuIL-12 after single SC injec-
tions in the FIH study are shown in Table 3. Sixteen of the
17 subjects who received rHuIL-12 (2 to 20 μg doses) had
measureable systemic drug concentrations. The initial and
terminal half-lives following an SC dose of rHuIL-12 could
not be determined at the 2 and 5 μg doses due to inad-
equate data. There were no obvious trends in Tmax with
increasing doses of rHuIL-12. The Cmax values generally
increased with increasing dose, with the exception of the
20 μg cohort, where only 1 subject was dosed. Area-
under-the-curve (AUC0-t) increased consistently as the
dose increased from 2 to 15 μg. At 20 μg. there was a de-
crease in AUC0-t, based on the available single-subject
data. Overall, increases in rHuIL-12 dose resulted in
greater exposure. There were no gender differences.
Phase 1b expansion study
In the expansion study, a subset of 40 of the 60 enrolled
subjects participated in the PK study. Of these, 32 were
Table 1 Number and percentage of subjects experiencing study drug related adverse events in the FIH study
System organ class/preferred term Placebo rHuIL-12 rHuIL-12 rHuIL-12 rHuIL-12 rHuIL-12 rHuIL-12
2 μg 5 μg 10 μg 12 μg 15 μg 20 μg
(N = 11) (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 1)
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Blood and Lymphatic System Disorders
Leukopenia 1 (100%)
Lymphopenia - - - - - - 1 (100%)
Neutropenia - - - - - 1 (25%)
Thrombocytopenia - - - - - - 1 (100%)
Gastrointestinal Disorders
Abdominal Distension - - - - 1 (25%) - -
Dyspepsia - - - - 1 (25%) - -
Nausea - - - - - - 1 (100%)
Paraesthesia Oral - - - - 1 (25%) - -
General Disorders and Administration Site Conditions
Chills - - - - 1 (25%) 1 (25%) 1 (100%)
Fatigue - - - - - 1 (25%) -
Feeling Abnormal - 1 (25%) - - - - -
Feeling Hot - - - - - - 1 (100%)
Injection Site Erythema 2 (18%) - - - 1 (25%) 1 (100%)
Injection Site Hemorrhage 1 (9%)
Injection Site Pain 1 (9%) 1 (25%) 1 (25%)
Injection Site Reaction 1 (9%) - - - 1 (25%) - -
Local Swelling - - - - 1 (25%) - -
Malaise - - - - - - 1 (100%)
Pain - - - - 1 (25%) - -
Infections and Infestations
Viral Infection - - 1 (25%) 1 (25%) - - -
Tonsillitis - 1 (25%) - - - - -
Musculoskeletal and Connective Tissue Disorders
Back Pain - - - 1 (25%) -
Myalgia - - 1 (25%) - - 1 (25%) –
Musculoskeletal Pain 1 (9%) - - - - - -
Nervous System Disorder
Headache 1 (9%) - - - 3 (75%) 3 (75%) 1 (100%)
Dizziness - - 1 (25%) 1 (25%) -
Hypoaesthesia - - 1 (25%) - - - -
Paraesthesia - - - - 1 (25%) - -
Presyncope 1 (25%) - - - -
Abbreviations: N total number of subjects in the dose group, n (%) number (%) of subjects who experienced each type of adverse event.
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cebo. Plasma rHuIl-12 was not detected in any of the 8
subjects who received placebo. All 32 subjects who re-
ceived rHuIL-12 had measureable systemic concentra-
tions after dosing, and endogenous rHuIL-12 was
detected in 1 of the 32 subjects before treatment withrHuIL-12. Mean PK parameters are shown in Table 3.
Systemic exposure of rHuIL-12 was variable, i.e., the co-
efficients of variance for Cmax, and AUC0-t were 86%,
60% respectively. As shown in Figure 1B, the rHuIL-12
concentration versus time profile appeared to be bi-
phasic, with an initial drop in plasma concentrations
Figure 1 Plasma concentration profiles of rHuIL-12 over time.
A) Plasma concentration vs. time for rHuIL-12 at 2, 5, 10, 12, 15 and
20 μg doses in the FIH study. B) Plasma concentration vs. time for
rHuIL-12 (12 μg) and for IFN-γ and CXCL10 in subjects treated with
rHuIL-12 at 12 μg in the phase 1b expansion study.
Table 2 Study drug related adverse events occurring in
≥ 5% of Subjects in the Phase 1b expansion study
System organ class (preferred term) Placebo rHuIL-12
12 μg
(N = 12) (N = 48)
Blood and Lymphatic System Disorders
Lymphadenitis 0 6 (13%)
Thrombocytopenia 0 3 (6%)
Eye Disorders
Photophobia 1 (8%) 0
Gastrointestinal Disorders
Nausea 3 (25%) 7 (15%)
Vomiting 1 (8%) 2 (4%)
General Disorders and Administration Site
Conditions
Chills 1 (8%) 11 (23%)
Fatigue 1 (8%) 7 (15%)
Feeling Hot 3 (25%) 5 (10%)
Injection Site Erythema 0 5 (10%)
Injection Site Pain 1 (8%) 5 (10%)
Injection Site Reaction 0 4 (8%)
Pain 0 3 (6%)
Investigations
Alanine Aminotransferase Increased 0 3 (6%)
Musculoskeletal and Connective Tissue
Disorders
Myalgia 1 (8%) 11 (23%)
Back Pain 0 10 (21%)
Arthralgia 0 3 (6%)
Musculoskeletal Stiffness 1 (8%) 2 (4%)
Neck Pain 1 (8%) 1 (2%)
Nervous System Disorders
Headache 4 (33%) 26 (54%)
Dizziness 0 5 (10%)
Abbreviations: N total number of subjects in the dose group, n (%) number (%)
of subjects who experienced each type of adverse event.
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prolonged phase occurring at approximately 56 hours
after dosing, suggesting significant distribution into the
extravascular spaces. The slower terminal phase could
be assessed only for 10 of the 32 subjects treated with
rHuIL-12. There were no gender differences in rHuIL-
12 exposure. Mean PK parameters from this study were
comparable to those observed at the 12 μg SC dose level
of rHuIL-12 in the FIH study.
Immunogenicity
Plasma samples from all subjects in both studies were
assayed for the presence of anti-drug antibodies torHuIL-12. In both studies, samples from all subjects
were tested at baseline (before dosing) and 28 days after
dosing. In the Phase 1b expansion study, immunogen-
icity testing also was performed at day 45 in a subset of
34 subjects who consented to additional sampling. No
confirmed anti-drug antibodies to rHuIL-12 were ob-
served at the specified time points in any subjects in
either treatment group in either study. Thus, there was
no evidence that any of the PD or PK parameters for
rHuIL-12 were confounded by the presence of anti-
rHuIl-12 antibodies.
Pharmacodynamics: hematological effects
As a part of the biological response to rHuIL-12, the
hematological effects on various blood cell types were char-
acterized over the course of the study. Neutrophils, plate-
lets, lymphocytes, reticulocytes were examined in both
studies, and specific lineages of lymphocytes and progenitor
cells were examined in the Phase 1b expansion study only.
Table 3 PK parameters for single dose rHuIL-12 in the FIH and Phase 1b expansion studies
PK Parameter
Study Dose Statistic Initial T½ Terminal T½ Tmax Cmax AUC 0-t
(μg) (h) (h) (h) (pg/mL) (h*pg/mL)
FIH
2 N 4 4 4 4 4
Mean ± SD NR NR 8.00 (8.00 – 8.00)a 5.55 ± 1.34 45.28 ± 11.30
5 N 4 4 4 4 4
Mean ± SD NR NR 5.00 (2.00 - 8.00)a 16.52 ± 2.87 154.22 ± 56.41
10 N 3 4 4 4 4
Mean ± SD 11.8 ± 1.79 89.56 ± 57.61 8.00 (5.00 - 8.00)a 26.39 ± 3.90 1169.86 ± 513.05
12 N 4 4 4 4 4
Mean ± SD 9.23 ± 5.78 48.92 ± NR 8.00 (8.00 - 12.00)a 45.41 ± 43.46 790.74 ± 305.24
15 N 4 4 4 4 4
Mean ± SD 8.71 ± 6.54 90.19 ± 68.49 5.00 (5.00 - 8.00)a 96.81 ± 57.12 1436.67 ± 602.18
20 N 1 1 1 1 1
Mean ± SD 7.22 83.05 12.00b 39.50 970.58
Expansion
12 N 27 10 32 32 32
Mean ± SD 8.74 ± 4.73 56.92 ± 42.20 8.00 (2.00 – 24.00)a 57.67 ± 49.84 1016.07 ± 612.97
Abbreviations: N number of subjects with sufficient data, NR not reported due to insufficient data, N/A not applicable, SD standard deviation.
aAll data are means (±SD), except for Tmax, which is presented as median (range).
bOnly 1 subject, range N/A.
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FIH study All 32 subjects were monitored for
hematological changes during the in-house stay (7 days)
and at return visits on days 11, 14 and 28. Time-
dependent, transitory changes in peripheral blood cell
counts were seen in subjects treated with rHuIL-12 over
the 28-day period, while counts remained more or less
stable following placebo treatment. Figure 2 indicates
the percentage change in lymphocyte, neutrophil, plate-
let, and reticulocyte counts relative to baseline in sub-
jects treated with placebo or rHuIL-12 at the different
dose levels. In rHuIL-12-treated subjects, lymphocytes
and platelets decreased after day 1 and reached their re-
spective nadirs between days 2 and 6; both types of cells
then gradually increased, exceeding the baseline level at
day 11 and returning to baseline by day 28. Neutrophils
initially increased on day 2 and then decreased, reaching
the nadir on day 5, and then followed the pattern ob-
served for lymphocytes and platelets. Reticulocytes de-
creased after day 1, reached the nadir on day 6, and then
followed the same pattern observed for lymphocytes,
platelets, and neutrophils.
At the 20 μg dose of rHuIL-12, the nadirs for lympho-
cytes, neutrophils, and platelets were 70%, 69%, and 29%
below baseline, respectively (based on data from one
subject), which constituted DLTs per protocol criteria
and led to a dose reduction from 20 μg to 15 μg, as de-
scribed above. At the 15 μg dose of rHuIL-12, nadirs forlymphocytes, neutrophils, and platelets ranged from 53%
to 69% below baseline, 33% to 64% below baseline, and
17% to 33% below baseline, respectively. A 64% decrease
in neutrophils in one subject met the criteria for a DLT,
as described above, and resulted in dose reduction to
12 μg. All DLTs were transitory.
Phase 1b expansion study All subjects were monitored
for hematological changes during the in-house stay for
16 days and at return visit on day 28. There was no dif-
ference in the absolute baseline counts for lymphocytes,
neutrophils, and platelets between the treatment groups.
These changes were similar to the transient decreases,
recovery and increases seen at the 12 μg dose of rHuIL-
12 in the FIH study. Figure 3 panel A describes mean
percentage changes from baseline in lymphocytes, neu-
trophils, platelets, and reticulocytes after rHuIL-12 treat-
ment. After dosing with rHuIL-12, treatment-related,
transient decreases in lymphocytes and platelets were
observed between days 2 and 8; both cell types returned
to baseline by days 8 to 9, increased above baseline
through day 16, and again returned to baseline by day
28. Similarly, neutrophils increased on day 2 and then
decreased from day 3 to 9, returned to baseline by day
10 and stabilized by day 28. Reticulocytes increased on
day 2, decreased from day 4 to 8, returned to baseline
on Day 10, increased above baseline between days 10
and 16, and returned to baseline by day 28. None of






































































































































































































































Figure 2 Transient hematological changes with different rHuIL-12 doses and placebo in the FIH study. The percentage changes from
baseline count after treatment with rHuIL-12 (2, 5, 10, 12, 15, or 20 μg) or placebo are shown as follows: A) lymphocytes/rHuIL-12; B) lymphocytes/
placebo; C) neutrophils/rHuIL-12; D) neutrophils/placebo; E) platelets/rHuIL-12; F) platelets/placebo; G) reticulocytes/rHuIL-12; H) reticulocytes/placebo.
Gokhale et al. Experimental Hematology & Oncology 2014, 3:11 Page 7 of 18
http://www.ehoonline.org/content/3/1/11these changes from baseline in any cell type were
deemed to be clinically significant. Similar transient
hematological changes were not seen after placebo treat-
ment (Figure 3A panel B).
Lymphocyte subpopulations and progenitor cells (expansion
study only)
In the expansion study, the transient hematological
changes described in Figure 3 Panels A and B were furthercharacterized using flow cytometry to detect specific line-
ages of blood cells such as CD3+, CD4+, CD8+ and CD45+
lymphocytes, NK cells, and CD34+ hematopoietic progeni-
tor cells, as well as rHuIL-12Rβ2 positivity on NK and
CD34+ progenitor cells, and mean fluorescence intensity
of CD56 on NK cells.
As shown in Figure 3, Panel C, treatment-related de-
creases for CD3+, CD4+, CD8+, and CD45+ lymphocytes































































































































































Figure 3 Transient hematological changes with 12 μg dose of rHuIL-12 or placebo in phase 1b expansion study. Standard hematologic
methods were used to determine cell counts at the indicated time points. The mean percentage of baseline count after treatment with rHuIL-12
(12 μg) or placebo are shown as follows: A) lymphocytes, neutrophils, platelets, and reticulocytes after treatment with rHuIL-12; B) lymphocytes,
neutrophils, platelets, and reticulocytes after treatment with placebo; C) CD45+, CD3+, CD4+ and CD8+ cells after rHuIL-12; D) CD45+, CD3+, CD4+
and CD8+ cells after rHuIL-12; D) NK and CD34+ after placebo; E) NK and CD34+ cells after rHuIL-12; F) NK and CD34+ cells after placebo. NK cells
were defined as CD45 + CD16 + CD56+ triple positive lymphocytes.
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returned to baseline by day 7, which paralleled the
changes in total lymphocytes (see Figure 3A), then tran-
siently increased, with a peak around day 11, and again
returned to baseline on day 28. The decrease from base-
line at the nadir was between 40% and 55% and the in-
crease from baseline at the peak was between 16% and
30%, depending on the cell type. Such changes were not
seen with placebo treatment.
NK cells represented nearly 10% of the total peripheral
blood cells, while the CD34+ progenitor cells accountedfor only 0.1% (data not shown). Figure 3, Panel E, shows
rHuIL-12 treatment-induced transient decreases in both
NK and CD34+ cells. NK cells reached a nadir at 20% of
the baseline level on day 2, and CD34+ cells reached a
nadir at 62% of baseline on day 4. Levels returned to
baseline by day 5 for NK cells and by day 7 for CD34+
progenitor cells. NK cells increased to baseline by day 5,
exceeded baseline starting on day 6, peaked on day 11,
and stabilized at a level 150% above baseline on day 14.
CD34+ cells increased to baseline at day 7, exceeded
baseline on day 9, and returned to the baseline level on
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CD34+ cells. With placebo treatment, both cell types
fluctuated above and below the baseline, but changes
were not comparable to those seen with rHuIL-12
treatment.
Cell surface expression of IL-12Rβ2, a unique subunit
of the heterodimeric receptor for rHuIL-12, was studied
to evaluate the effect of rHuIL-12 on the receptor posi-
tivity of NK and CD34+ progenitor cells. Over the course
of the study, about 50% of the NK and CD34+ progeni-
tor cells were IL-12Rβ2+, which represented approxi-
mately 5% and 0.05% of total peripheral blood cells,
respectively. As shown in Figure 4A, rHuIL-12 treatment
did not affect the number of IL-12Rβ2+ cells relative to
that observed with placebo, although more fluctuations
were seen in the number of receptor-positive CD34+
progenitor cells than in the number of receptor-positive
NK cells.
Mean fluorescence intensity of CD56 on NK cells was
increased with rHuIL-12 administration, peaking on day














































Figure 4 Effect of rHuIL-12 or Placebo on rHuIL-12Rβ2 Positivity and
Study. Flow cytometry was used to determine A) changes in the percenta
(12 μg) or placebo; and B) changes in CD56 mean fluorescence intensity o
were defined as CD45 + CD16 + CD56+ triple positive lymphocytes.such changes were seen with placebo treatment. Overall,
flow cytometric analysis showed that a single administra-
tion of rHuIL-12 to healthy subjects resulted in a rapid
decreases in various types of peripheral blood cells
followed by recovery at differing rates and extents.
Pharmacodynamics: immunological effects
PD responses to rHuIL-12 were measured by quantifying
levels of IFN-γ (both studies) as well as erythropoietin
(EPO), interleukin-18 (IL-18) and CXCL10 (expansion
study only).
FIH study
IFN-γ levels were not quantifiable (i.e., they were below
the lower limit of quantification [LLOQ]) in response to
2 and 10 μg doses of rHuIL-12. At other doses of
rHuIL-12, the Tmax of IFN-γ (15 to 72 hours after
rHuIL-12) was delayed relative to the Tmax of rHuIL-12
itself (5 to 12 hours after dosing), which is indicative of
a PD response (data not shown). However the exposure
values for IFN-γ were quite variable and the compositeys






6 8 10 12 14
Placebo
rHuIL-12
CD56 Mean Fluorescence Intensity in the Phase 1b Expansion
ge of rHuIL-12Rβ2 positive NK and CD34+ cells in response to rHuIL-12
n NK cells in response to dose of rHuIL-12 (12 μg) or placebo. NK cells
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ship. Mean Cmax values were 272 ± 176 pg/mL, 215 ±
148 pg/mL, 287 ± 181 pg/mL and 410 pg/mL respectively
in response to 5, 12, 15 and 20 μg doses of rHuIL-12 and
the mean AUC0-t values were 13,962 ± 17,034 h*pg/mL,
13,984 ± 4473 h*pg/mL, 10,822 ± 6,994 h*pg/mL and
27,437 h*pg/mL respectively after 5, 12, 15 and 20 μg
doses of rHuIL-12. The detection of systemic IFN-γ after
rHuIL-12 dosing at 5 μg, but not at 10 μg was unexpected.
Expansion study
Endogenous IFN-γ was detected in 1 of the 32 subjects
before treatment with rHuIL-12. A measureable IFN-γ
response was observed 28 of the 32 subjects treated with
rHuIL-12 (Figure 1B), but in none of the 8 subjects who
received placebo (data not shown), indicating a positive
PD response to rHuIL-12 treatment. The median IFN-γ
Tmax value (24 hours) was delayed in time relative to the
median rHuIL-12 Tmax value (8 hours; Figure 1B). Mean
AUC0-t value was 27,088 ± 22,380 h*pg/mL. There were
no gender differences in IFN-γ response to rHuIL-12
(data not shown).
Endogenous EPO was detected prior to treatment with
study drug in all 32 subjects. Over the 14 day period fol-
lowing SC injection of study drug, EPO levels fluctuated
in both treatment groups, without any apparent re-
sponse to rHuIL-12 treatment (Figure 5A).
Endogenous IL-18 also was detected prior to treat-
ment with study drug, and, unlike EPO, showed a defin-
ite response to rHuIL-12 between 36 hours and 14 days
after treatment with rHuIL-12 (Figure 5B). By compari-
son, IL-18 levels remained relatively close to baseline in
the placebo-treated group (Figure 5B). Median Tmax
(107 hours) for IL-18 in the rHuIL-12 group was delayed
relative to the median Tmax for rHuIL-12 (8 hours; data
not shown). Male subjects had a significantly higher (p ≤
0.0002) IL-18 response than did females (data not shown).
Like EPO and IL-18, endogenous CXCL10 was de-
tected prior to treatment with study drug. A PD re-
sponse to rHuIL-12 was observed between 36 hours and
3 days after rHuIL-12 treatment, relative to placebo
treatment (Figure 5C). The median CXCL10 Tmax (24
hours) in subjects treated with rHuIL-12 was delayed
relative to the median Tmax for rHuIL-12 itself (8 hours;
Figure 1B). In the placebo-treated group, only 2 of the 8
subjects showed a measurable CXCL10 response (data
not shown), and the mean Cmax was significantly lower
than that of the rHuIL-12-treated group (1480.53 pg/mL
with placebo vs. 2055.53 pg/mL with rHuIL-12; p < 0.03
by T-test on log transformed data). This difference may
be confounded, however, by the extent and variability of
endogenous levels observed in placebo-treated subjects
(data not shown). There were no gender differences in
the CXCL10 response to rHuIL-12 (data not shown).Discussion
The FIH and Phase 1b expansion studies reported here
were designed to study the safety of rHuIL-12 when ad-
ministered as a single SC dose of up to 20 μg in healthy
subjects and to characterize the PK profile and
hematological and immune-mediated effects of rHuIL-
12. Characterization of IL-12’s effects in normal healthy
subjects with intact immune systems is essential for fur-
ther development of rHuIL-12 as a hematopoietic and
immunotherapeutic agent for conditions such as HSARS
or cancer.
The FIH study used a conservative range of single 2 to
20 μg doses, which are equivalent to 0.03 to 0.3 μg/kg in
a 70 kg person. The SC route was chosen as it repre-
sents the route of choice for a front line medical radi-
ation countermeasure and is also appropriate for cancer
patients based on historical data showing that SC ad-
ministration of IL-12 limited the toxic effects observed
with intravenous treatment [29,30].
Per protocol, dose reductions were required in the
event that one or more subject experienced a single
Grade 3 change in clinical laboratory values, based on a
stringent toxicity grading scale for healthy subjects [31].
At the 20 μg dose, the sentinel subject experienced
Grade 3 thrombocytopenia and lymphopenia; thus, no
additional subjects were dosed in this cohort. An add-
itional cohort was enrolled at the reduced dose level of
15 μg, and one of 4 rHuIL-12-treated subjects experi-
enced Grade 3 neutropenia. An additional cohort was
therefore enrolled for treatment at an intermediary dose
of 12 μg. As no DLTs were observed in this final cohort,
the MTD was determined to be 12 μg. None of the
drug-related, severe cytopenias observed in the FIH
study resulted in any clinically significant manifestations
and the absolute platelet and neutrophil counts were
well above the levels which are considered predisposing to
hemorrhagic or infectious episodes. No non-hematologic
DLTs associated with rHuIL-12 occurred at any doses in
the FIH study. The tolerability of the MTD identified in
the FIH study (12 μg) was confirmed in the expansion
study, as no clinically significant changes in vital signs,
ECGs and physical examinations were observed in either
study.
The most common AEs related to rHuIL-12 treatment
in both studies were headache, dizziness, and chills.
These AEs were expected and have been documented in
previous studies as flu-like symptoms [10,30,32-34]. Inci-
dence of fever was 39% in an earlier study of healthy vol-
unteer [10] that used similar doses of IL-12, while it was
2% in our study. Thus, rHuIL-12 administered as single,
SC doses up to 12 μg was found to be safe and well tol-
erated in healthy subjects in these studies.
Data from these studies showed that rHuIL-12 in-


































































































Figure 5 Effect of rHuIL-12 or Placebo on EPO, IL-18 and CXCL10 levels in the Phase 1b expansion study. EPO, IL-18, and CXCL10 were
measured at the indicated time points using validated assays. The mean changes from baseline after treatment with rHuIL-12 (12 μg) or placebo
are shown as follows: A) EPO; B) IL-18; C) CXCL10.
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and reticulocytes as well as subpopulations of lympho-
cytes, i.e., CD3+, CD4+, and CD8+ cells, NK cells, and
CD34+ hematopoietic progenitor cells. All of these cell
populations subsequently recovered at different rates
and resolved to their pre-dose baseline levels, or slightlyabove. The early onset and rapid reversibility of these
changes indicate that they do not result from suppres-
sion of proliferation of hematopoietic precursors and
progenitors in bone marrow, which otherwise would be
expected to start later and last longer. These transient
hematological changes can be explained on the basis of
Gokhale et al. Experimental Hematology & Oncology 2014, 3:11 Page 12 of 18
http://www.ehoonline.org/content/3/1/11trafficking and redistribution of cells from the central
blood compartment, e.g., neutrophil margination and exit
into tissues, and lymphocyte redistribution to lymphoid
organs. An additional explanation could be the delayed re-
lease of mature cells from the bone marrow post-mitotic
compartments. The transient changes in neutrophil and
lymphocyte counts observed in our studies have been re-
ported by others [10,30,32,34,35]. However the rHuIL-12-
induced transient changes in platelets and reticulocytes
are novel findings in our study. We have not yet studied
the underlying mechanism for these changes. However
similar findings with respect to platelets have been re-
ported with rHuIL-10, where a mild reversible decline in
platelet counts was seen following 10 daily doses in
healthy subjects [36]. Viability of the platelets was not af-
fected in that study.
In addition to the parameters described above, safety
also was assessed by testing for the development of anti-
rHuIL-12 antibodies using a validated assay. Results
showed no evidence of immunogenicity associated with
rHuIL-12 in the FIH study (measured after 28 days) or
the expansion study (measured after 45 days).
To our knowledge, this is the first report of a detailed
PK analysis for rHuIL-12 in human subjects. The vali-
dated ELISA used to measure systemic concentrations of
rHuIL-12 was sensitive enough to detect rHuIL-12 levels
at all dose levels examined. There were no gender differ-
ences in rHuIL-12 exposure. Elimination of rHuIL-12
was biphasic with a short initial half-life of 8 to 24 hours
measurable in all subjects and a prolonged terminal
half-life > 50 hours measurable only in 47% subjects,
possibly due to limitation of the rHuIL-12 assay. This
terminal half- life possibly represents a slow return of
rHuIL-12 to the central compartment from the tissues,
and/or slow absorption from the SC space via the lym-
phatics and/or capillaries. Another explanation could be
the secondary expression of endogenous IL-12 produced
through a positive feedback loop [37]. In the FIH study,
the rHuIL-12 exposure generally increased with increase
in the dose. Overall, rHuIL-12 PK exposure in both
studies was highly variable. The clearance and volume of
distribution could not be reliably determined due to the
lack of sufficient data in the terminal phase.
IL-12 is known to up-regulate adhesion molecules.
In vitro studies have demonstrated that IL-12 is chemo-
tactic to NK cells and stimulates adhesion of NK cells to
endothelial cells and platelets via activation and in-
creased expression of cell-cell adhesion molecules CD56
and CD11a [38,39]. The margination effect of lympho-
cytes and increased expression of adhesion molecules on
NK cells was also demonstrated in cancer patients
treated with IL-12 [35]. CD34 is also an important adhe-
sion molecule required for T cells to enter lymph nodes
[40,41]. In the expansion study, expression of CD56levels as measured by mean fluorescence intensity in-
creased after rHuIL-12 administration, while no such in-
crease was seen in response to placebo. There also was
an increase in CD34+ cells in response to rHuIL-12, but
not with placebo. These observations provide a mechan-
istic explanation for the transient hematological changes.
In addition, analysis of NK and CD34+ progenitor cells
for IL-12Rβ2 positivity confirmed that these cells can be
directly targeted by rHuIL-12. During the course of the
study, relative percentages of IL-12Rβ2+ cells after rHuIL-
12 treatment were similar to those observed after placebo
treatment, suggesting that rHuIL-12 did not down regu-
late IL-12Rβ2 within these two cell populations.
Overall the hematological changes observed in both
studies suggest that rHuIL-12 induces trafficking of per-
ipheral blood cells from the vasculature to the tissues as
a part of normal immune surveillance. Interestingly, the
effect of rHuIL-12 on peripheral blood cells was multili-
neage, affecting all major blood cell types. To the best of
our knowledge, this is the first example of a single cyto-
kine that simultaneously induces a decline followed by
recovery of lymphocytes, neutrophils, platelets, reticulo-
cytes, as well as subpopulations of lymphocytes. We
speculate that these changes are resulting from the acti-
vation and distribution of the cells into tissues. Defini-
tive studies are needed to understand this phenomenon.
Data relevant to our speculation have been reported be-
fore in nonclinical and clinical studies. Gately et al. [42]
have reported a study where livers of IL-12 treated mice
revealed focal mononuclear cell infiltrates. The livers
contained increased numbers of NK cells, CD8+ T cells,
and monocytes. Also the liver and splenic lymphoid cells
from these IL-12-treated mice spontaneously secreted
IFN-γ in vitro, suggesting that they had been induced by
IL-12 to produce IFN-γ in vivo. This was indeed con-
firmed as IFN-γ levels were detected in the serum of IL-
12-treated mice. In another murine study, Jackson et al.
[43] reported that a single injection of recombinant
murine IL-12 significantly reduced the number of bone
marrow colony-forming unit granulocyte-macrophage
(CFU-GM) in a time-dependent manner, while concomi-
tantly stimulating high proliferative potential (HPP). In
contrast, splenic CFU-GM and HPP were increased in a
time- and dose-dependent manner. These data showed
that IL-12 exerts in vivo hematopoietic effects that
include the ability to mobilize progenitor cells to the
peripheral circulation. In a clinical study in metastatic
melanoma patients, Mortarini et al. [44] have reported
that the SC administration of human recombinant IL-12
promoted the infiltration of neoplastic lesions by CD8+
T-cells with a memory phenotype.
The hallmark effect of IL-12 in immunity is its ability
to stimulate the production of IFN-γ from NK cells,
macrophages and T cells [6,10]. CXCL10 is a chemokine
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tion, while IL-18 plays important roles in the develop-
ment, homeostasis, and functions of CD4+ T cells, CD8+
T cells, and NK cells [45,46]. Additionally EPO was also
analyzed as a systemic measure of rHuIL-12 activity based
on its biological functions, other than erythropoiesis, that
have been unraveled after finding EPO receptors on cells
other than erythroid progenitors, such as polymorpho-
nuclear leukocytes, megakaryocytes, and endothelial, myo-
cardial, and neuronal cells [47-52]. EPO production was
stimulated by rHuIL-12 in non-irradiated and irradiated
NHP and mice demonstrating a potential central role in
mediating the radiomitigation activity [6]. Thus induc-
tion and interrelationship between rHuIL-12 and a
battery of these biological response parameters was
studied in healthy human subjects.
The PD parameters in these studies were selected based
on their relevance to immune-mediated effects of IL-12
that have been well documented in vitro [38,53,54], as well
as in animal models [6] and clinical studies [19,55-61]. In
our studies, IFN-γ, IL-18 and CXCL10 were found to be
useful as downstream positive biological response parame-
ters in support of the immunomodulatory activities of
rHuIL-12. The IFN-γ response was consistently detected
in both studies. The relatively delayed Tmax together with
the lack of endogenous IFN-γ indicate that this is a true
biological IFN-γ response, which is known to be mediated
via differentiation of TH1 cells. CXCL10 is another sensi-
tive marker of induction of TH1-like innate immune acti-
vation manifested by IFN-γ, as well as directly stimulated
by IL-12 [62,63]. Significantly higher levels of CXCL10
were detected in response to rHuIL-12, although results
were confounded by variable endogenous levels. Based on
the PD effects observed in these studies, we hypothesize
that a single, low dose of exogenous rHuIL-12 is a trigger
for multilineage hematopoietic stimulation and innate im-
mune responses, which is unique and not achievable with
currently used hematopoietic growth factors.
Currently rHuIL-12 is being developed as a radiation
countermeasure under the provisions of FDA’s Animal
Rule [28]. Nonclinical studies in rhesus monkeys have
shown a similar pattern of transient hematological
changes and immune responses with rHuIL-12 treat-
ment in normal monkeys. Further, in the studies where
monkeys were subjected to lethal total body irradiation,
single, low doses of rHuIL-12 in the range of 50 to 500
ng/kg demonstrated an increased survival benefit in the
absence of any supportive care (i.e., no antibiotics, fluids
or blood products). The safe and well-tolerated human
dose of 12 μg (171 ng/kg based on 70 kg human body
weight) is within this efficacious range based on expos-
ure parameters [64]. Based on these results, rHuIL-12 is
being developed under the FDA Animal Rule approval
pathway as a frontline therapy in humans to mitigateradiation-induced damage and increase the potential for
survival in the event of a nuclear disaster or accident.
We also have reported that low-dose, adjuvant IL-12
promotes multilineage hematopoietic recovery from can-
cer therapy-induced cytopenias, along with concomitant
anti-tumor responses, in tumor-bearing mice [65]. Thus,
results from these animal and human studies of rHuIL-
12 also can be applied towards clinical trials in oncology,
with the aim of reducing both toxicity and tachyphylac-
tic effects that result from repeated high-dose regimens
of IL-12, thereby augmenting antitumor effects.
Conclusions
The observations from these studies indicate that a sin-
gle low dose of rHuIl-12 administered subcutaneously
can elicit hematological and immune-mediated effects
without undue toxicity. The potent hematological and
immune effects observed in our studies suggest that
rHuIL-12, when dosed in a prudent manner, can be
safely used to support the hematopoietic system and
provide immunotherapeutic benefits in individuals ex-
posed to lethal radiation, as well as in patients with mye-
losuppression resulting from either chemotherapy or
radiation therapy.
Methods
The clinical studies reported here have been approved
by the Institutional Review Board (Independent IRB
Inc., Fort Lauderdale FL 33323). All clinical investiga-
tions have been conducted according to the principles
expressed in the Declaration of Helsinki and registered
at ClinicalTrials.gov.
Subjects
A total of 32 healthy subjects were enrolled in the first-
in-human (FIH) study and 60 subjects were enrolled in
the expansion study. Written informed consent (ap-
proved by the Independent IRB Inc., Ft. Lauderdale, FL)
was obtained from all subjects prior to their participation
in the study. Male and female healthy subjects between 18
and 45 years of age, with a body mass index > 19 and <
30 kg/m2, and normal ECG, physical examination, and la-
boratory results, and females with negative pregnancy test
or not breastfeeding were enrolled in the study. Subjects
with history of drug or alcohol addiction, food or drug al-
lergies, or who had previously used IL-12 or were unable
or unwilling to practice effective contraception were ex-
cluded. Use of ibuprofen was allowed to a total dosage of
up to 2400 mg/day for flu-like symptoms experienced
after study drug administration.
Study design
The primary endpoint for both studies was safety and
tolerability of rHuIL-12. Secondary endpoints were
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FIH study was conducted between 01 June 2011(first
subject enrolled) and 20 March 2012 (last subject com-
pleted). The phase 1b expansion study was conducted
between 05 August 2013 (first subject enrolled) and 03
November 2013 (last subject completed). Both studies
were stopped following completion of the final study
visit for the final subject. Subjects were enrolled by
study staff. Randomization in both studies was accom-
plished using SAS®-generated randomization sequences
(SAS® Institute Inc. Cary, North Carolina) that were
assigned to subjects by an unblinded research staff
member. All other research staff, subjects, care pro-
viders, and the sponsor were blinded to the treatment
assignment.
In the double-blind FIH study, eligible subjects were
enrolled in consecutive cohorts to receive either a single
subcutaneous dose of rHuIL-12 (2, 5, 10, 20 μg) or pla-
cebo. Randomization for each cohort was 4:2 (rHuIL-12:
placebo). Sentinel subjects, defined as the first subject in
each cohort to receive rHuIL-12 and the first subject in
each cohort to receive placebo were dosed at the begin-
ning of each cohort. The starting 2 μg dose of rHuIL-12
was derived from allometric scaling of approximately
one tenth of the NOAEL from rhesus monkey toxicology
studies (Neumedicines, Inc., unpublished data), in ac-
cordance with FDA guidelines [31]; B), historical data
from healthy subjects treated with a single dose (1 to
8 μg) of a different formulation of rHuIL-12 [10]; and C)
data from patients with various types of cancer treated
with rHuIL-12 at doses ranging from 0.003 to 1.25 μg/kg)
[29,30]. Due to the occurrence of DLTs in the sentinel
subject treated at the 20 μg dose level, an additional co-
hort of 6 subjects was randomized to rHuIL-12 at 15 μg
or placebo, and due to the occurrence of a DLT in the
final subject in that cohort, an additional cohort of 6 sub-
jects was enrolled for treatment at 12 μg of rHuIL-12 or
placebo. Thus, a total of 32 subjects were enrolled and
randomized.
Subjects were admitted to the research facility at the
Covance Clinical Research Unit (Madison, WI), 12 hours
prior to study drug administration. Study drug was ad-
ministered subcutaneously on day 1 following baseline
assessments. Subjects resided in the research facility for
7 consecutive days and returned on days 11, 14 for in-
terim visits and on day 28 for the close‐out visit. Blood
samples for clinical chemistry and hematology assess-
ments were collected at screening, baseline (day 1), and
on days 2 to 7, 11, 14 and 28. PK samples were collected
on day 1 (within 1 hour predose, and at 1, 2, 5, 8, 12,
and 24 hours postdose) and daily on days 3 to 7, 11, and
14. PD samples were collected at screening, on day 1
(within 1 hour predose; at 5, 12, and 24 hours post
dose), and daily on days 3 to 7, 11 and 14. Samples forimmunogenicity testing were collected on day 1 (within
1 hour predose) and on day 28.
In the double-blind Phase 1b expansion study, eligible
subjects were randomized at a 4:1 ratio to receive either
a single subcutaneous 12 μg dose of rHuIL-12 or pla-
cebo and were dosed in three consecutive groups. Sub-
jects were admitted to the research facility at Covance
Clinical Research Unit (Madison, WI), 12 hours prior to
study drug administration. Study drug was administered
on day 1 following baseline assessments. Subjects re-
sided in the research facility for 16 consecutive days and
returned to the facility on day 28 and on day 45 (only
those who consented per the amended protocol) for im-
munogenicity testing. The 16 day in-house stay facili-
tated thorough hematological analyses. Blood samples
were collected for clinical laboratory investigations and
immunogenicity tests from all 60 subjects at screening,
daily on days 1 (within 1 hour pre-dose) to 16 and 28.
Samples for PK and PD analyses were collected only
from the subset of 40 subjects. PK samples were col-
lected on day 1 (within 1 hour pre-dose and at 1, 2, 5, 8,
12 and 24 hr post dose); then daily on days 3 to 7. PD
samples were collected on day −1, day 1 (within 1 hour
predose and at 5, 12 and 24 hours post dose), then daily
on days 3 to 7, 11, and 14. Peripheral blood samples for
the flow cytometry analysis were collected on day-1, day
1 (within 1 hour pre-dose); then daily on days 2 to 7, 9,
11, and 14. Samples for immunogenicity testing were
collected on day 1 (within 1 hour pre-dose) and on day
28 (all subjects) and day 45 (only for 34 subjects who
consented to additional sampling).Analysis of safety
The safety and tolerability of rHuIL-12 were assessed by
physical examination, vital sign measurements, labora-
tory tests, ECGs, and monitoring and reporting of ad-
verse events (AEs). DLTs and AE severity were based on
the FDA 2007 guidance on toxicity grading for healthy
adult and adolescent volunteers enrolled in preventive
vaccine clinical trials [31] with additional modifications
by the FDA. For the FIH study only, this scale was modi-
fied with more stringent criteria for clinical and labora-
tory abnormalities. As only one dose of rHuIL-12 was
given, subjects were not withdrawn from the study as a
result of a DLT. All AEs were mapped to preferred terms
and body systems using MedDRA version 15.1. Descrip-
tive statistics were used for demographics, baseline char-
acteristics; frequencies and percentages were used for
adverse events by treatment assignment. In the expan-
sion study, subjects from all 3 groups were combined to
form the placebo and rHuIL-12 groups for comparison
of endpoints. In both studies, the safety analysis popula-
tion included all subjects who were randomized.
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A complete blood count (CBC) was done using a
routine validated procedure at the local laboratory
contracted by the Covance Clinical Research Unit
(Madison, WI). Flow cytometric detection of immuno-
phenotypes within the lymphocyte population, i.e.
CD3+, CD4+, and CD8+ lymphocytes, was done at the
Covance Immunotoxicology Laboratory (Madison,WI)
using a 4-color Multitest Kit (BD Biosciences; San
Diego, CA; Cat #3400491).
Additionally, NK cells and circulating hematopoietic
progenitors were measured by flow cytometry. NK cells
were defined to be the CD45+CD16+CD56+ lymphocyte
population, and circulating hematopoietic progenitors
were defined to be CD45+CD34+ leukocytes. NK cell
gating was performed in two steps: firstly, lymphocytes
were gated using CD45 and side scatter, followed by gat-
ing on CD16+CD56+ double-positive population. CD3
negativity was not used for NK cell gating. Dead cells
were eliminated based on 7AAD positivity. IL-12Rβ2
positivity was further determined on the NK and CD34+
cells. Fluorescently labeled antibodies against 7-AAD,
CD45, CD56, CD16, and CD34, were purchased from
BD Biosciences (San Jose, CA; Cat. #559925, 641399,
557699, 557744, and 348057, respectively) and the anti-
IL-12 Rβ2 antibody, was purchased from R&D Systems
(Minneapolis, MN; Cat. #FAB1959A). Entire gating strat-










Figure 6 Gating strategy for flow cytometry in Phase 1 b expansion sBioanalytical assays
All enzyme linked immunosorbent assay (ELISA) methods
were validated in human K2 EDTA plasma using commer-
cially available kits and antibodies. These assays were per-
formed at Intertek Pharmaceutical Services, San Diego,
CA. Assay systems and LLOQ were as follows: rHuIL-12 -
Quantikine® HS Human IL-12 High Sensitivity ELISA
Kit, (R&D Systems; Minneapolis, MN; Cat. #HS120,
SS120, or PHS120) and LLOQ = 3.75 pg/mL; IFN-γ.
Human Interferon-γ (IFN-γ) ELISA MAX™ Deluxe Sets,
(BioLegend Inc.; San Diego, CA; Cat. #430106) and
LLOQ = 30.00 pg/mL; EPO - Quantikine® IVD® Erythro-
poietin ELISA kit, (R&D Systems; Cat. #DEP00) and
LLOQ= 2.00 mIU/mL; IL-18 - Human IL-18 ELISA Kit,
MBL (Japan), distributed by R&D Systems (Cat #7620)
and LLOQ= 25.60 pg/mL; CXCL10 - Quantikine® Human
CXCL10 Immunoassay ELISA Kit, (R&D Systems; Cat.
#DIP100) and LLOQ= 12.00 pg/mL. Immunogenicity
testing (anti rHuIL-12 antibodies) used a tiered cut-point
titration method validated at Intertek Pharmaceutical
Services, utilizing anti-human IL-12 (p70) antibody (Bio-
Legend Inc.; Cat. #511002); LLOQ was not applicable.
Pharmacokinetic and pharmacodynamic analyses
Plasma PK analyses for rHuIL-12, and PD analyses
for IFN-γ, EPO, IL-18 and CXCL10 were performed
by ProPharma Services LLC, Superior CO using non-
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http://www.ehoonline.org/content/3/1/11Version 6.3 or higher (Pharsight Corporation; Mountain
View, California). Nominal dose and actual weight and
sampling times were used. Summary statistics were pre-
pared with WinNonlin and Microsoft® Excel 2007 (Seattle,
WA), while mean and individual concentration graphs
were prepared with Prism™ Version 5.0 (GraphPad Soft-
ware, Inc.; La Jolla, CA). Descriptive statistics were pro-
vided for PK and PD by treatment and by gender.
Group and gender comparisons of means for Cmax,
AUC0-t and AUC0-∞ values were conducted via a t-test
with log-transformed data using MedCalc® version
12.2.1.0 (Mariakerke, Belgium).
Flow cytometry analysis
Fluorescence-activated cell sorting (FACS) DIVA® software
Version 6.1.3 (BD Biosciences; San Diego, CA) was used
for data acquisition and analysis at the Covance Immuno-
toxicology Laboratory (Madison,WI) and Neumedicines
Inc., Pasadena CA.
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